초록 ▼

The present disclosure provides methods of integrating therapeutic protein and antibody generation and/or selection, evolution and expression in a eukaryotic host for manufacturing in a single system. Therapeutic proteins, including antibodies, are generated, optimized and manufactured in the same e

The present disclosure provides methods of integrating therapeutic protein and antibody generation and/or selection, evolution and expression in a eukaryotic host for manufacturing in a single system. Therapeutic proteins, including antibodies, are generated, optimized and manufactured in the same eukaryotic host system. The disclosed system of Comprehensive Integrated Antibody Optimization (CIAO!™) allows for simultaneous evolution of protein performance and expression optimization.

대표청구항 ▼

1. A method of evolution and expression of an antibody in a mammalian cell production host; the method comprising: a. evolving a template antibody to produce a set of mutant antibodies in a mammalian cell production host with antibody cell surface display, wherein the template antibody consists of a

1. A method of evolution and expression of an antibody in a mammalian cell production host; the method comprising: a. evolving a template antibody to produce a set of mutant antibodies in a mammalian cell production host with antibody cell surface display, wherein the template antibody consists of an intact immunoglobulin molecule or a fragment of an immunoglobulin molecule and has a total of n amino acid residues, and said evolving comprises generating n-1 separate sets of mutant antibodies from the template antibody, each set comprising member antibodies having 19 different predetermined amino acid residues at a single predetermined position of the antibody, wherein each set of antibodies differs in the single predetermined position, and the number of different member antibodies generated is equivalent to [n−1]×19;b. screening the mutant antibodies for the at least one predetermined property, characteristic or activity;c. selecting an up-mutant antibody from the set of mutant antibodies based upon optimization of the at least one predetermined property, characteristic or activity compared to the template antibody; andd. expressing the up-mutant antibody in the same mammalian cell production host as was used in step (a). 2. The method of claim 1, wherein step (a) comprises steps of: a1. generating an anti-antigen antibody library in the mammalian cell production host with antibody cell surface display;a2. screening the library for the at least one predetermined property, characteristic or activity; andwherein the template antibody is selected from the library. 3. The method of claim 1 wherein the mammalian cell production host is selected from a member of the group consisting of 3T3 mouse fibroblast cells; BHK21 Syrian hamster fibroblast cells; MDCK, dog epithelial cells; Hela human epithelial cells; PtK1 rat kangaroo epithelial cells; SP2/0 mouse plasma cells; and NS0 mouse plasma cells; HEK 293 human embryonic kidney cells; COS monkey kidney cells; CHO, Chinese hamster ovary cells; R1 mouse embryonic cells; E14.1 mouse embryonic cells; H1 human embryonic cells; H9 human embryonic cells; PER C.6, human embryonic cells. 4. The method of claim 1, wherein the mammalian cell production host is CHO-S or HEK293. 5. The method of claim 1 wherein the screening step comprises fluorescence-activated cell sorting. 6. The method of claim 1 wherein the antibody is an antibody fragment selected from a heavy chain, light chain, variable domain, constant domain, hypervariable region, complementarity determining region 1, complementarity determining region 2, and complementarity determining region 3. 7. The method of claim 1, wherein the screening step (c) comprises: i. assaying each member antibody for at least one predetermined property, characteristic or activity;j. identifying any change in said property, characteristic or activity of the member antibody relative to the template antibody;k. creating a functional map wherein the functional map is used to identify positions and mutations in the mutant antibody which result in an up-mutant and/or a silent mutation compared to the template antibody. 8. The method of claim 1, wherein said evolving step comprises: i. subjecting a codon-containing polynucleotide encoding for said template antibody to polymerase-based amplification using a 64-fold degenerate oligonucleotide for each codon to be mutagenized, wherein each of said 64-fold degenerate oligonucleotides is comprised of a first homologous sequence and a degenerate N,N,N triplet sequence, so as to generate a set of progeny polynucleotides; andii. subjecting said set of progeny polynucleotides to clonal amplification such that the mutant antibodies encoded by the progeny polynucleotides are expressed. 9. The method of claim 7 wherein the functional map is used to identify one or more of (a) positions and mutations which do not affect the activity of the mutant antibody compared to the template antibody; (b) fully mutable sites compared to the template antibody; and (c) positions and mutations which result in an up-mutant compared to the template antibody. 10. The method of claim 1 wherein the at least one predetermined property, characteristic or activity is selected from reduction of protein-protein aggregation, enhancement of protein stability, increased protein solubility, introduction of glycosylation sites, introduction of conjugation sites, reduction of immunogenicity, increase in antigen affinity, decrease in antigen affinity, change in binding affinity, change in immunogenicity, and enhancement of specificity. 11. The method of claim 2, wherein the anti-antigen antibody library is a humanized anti-antigen antibody library. 12. The method of claim 1 wherein the screening step comprises creating a functional map that is capable of being used to identify positions and mutations in the mutant antibodies which result in an up-mutant and/or a silent mutation compared to the template antibody. 13. The method of claim 3, wherein the mammalian cell production host is CHO cells. 14. The method of claim 1, further comprising a step of confirming by sequencing a presence of the predetermined amino acid residues at the single predetermined position in each member antibody.